Obstetric antiphospholipid syndrome

Antiphospholipid syndrome (APS) in pregnancy has a serious impact on maternal and fetal morbidity. It causes recurrent pregnancy miscarriage and it is associated with other adverse obstetric findings like preterm delivery, intrauterine growth restriction, preeclampsia, HELLP syndrome and others. The...

Descripción completa

Detalles Bibliográficos
Autores Principales: Galarza-Maldonado, Claudio, Kourilovitch, Maria R., Pérez-Fernández, Oscar M., Gaybor, Mariana, Cordero, Christian, Cabrera, Sonia, Soroka, Nikolai F.
Formato: Artículo (Article)
Lenguaje:Inglés (English)
Publicado: 2012
Materias:
Acceso en línea:https://repository.urosario.edu.co/handle/10336/23166
https://doi.org/10.1016/j.autrev.2011.10.006
id ir-10336-23166
recordtype dspace
spelling ir-10336-231662022-05-02T12:37:20Z Obstetric antiphospholipid syndrome Galarza-Maldonado, Claudio Kourilovitch, Maria R. Pérez-Fernández, Oscar M. Gaybor, Mariana Cordero, Christian Cabrera, Sonia Soroka, Nikolai F. Acetylsalicylic acid Antibody Antithrombin Autoantibody Beta 2 glycoprotein 1 antibody Betamethasone Cardiolipin antibody Dalteparin Dexamethasone Enoxaparin Heparin Low molecular weight heparin Lupus anticoagulant Nadroparin Prednisolone Prednisone Unclassified drug Warfarin Antibody detection Antiphospholipid syndrome Autoimmune disease Human Hypercoagulability Laboratory test Low drug dose Morbidity Nonhuman Preconception injury Pregnancy Puerperium Review Spontaneous abortion Standardization Teratogenicity Thrombosis Vascular disease Animals Antibody-dependent cell cytotoxicity Antiphospholipid syndrome Aspirin Blood coagulation Female Heparin Humans Immunotherapy Individualized medicine Mice Pregnancy Pregnancy complications Antiphospholipid antibodies Obstetric antiphospholipid syndrome Recurrent pregnancy miscarriage animal antiphospholipid habitual Abortion Antibodies Disease models Antiphospholipid syndrome (APS) in pregnancy has a serious impact on maternal and fetal morbidity. It causes recurrent pregnancy miscarriage and it is associated with other adverse obstetric findings like preterm delivery, intrauterine growth restriction, preeclampsia, HELLP syndrome and others. The 2006 revised criteria, which is still valid, is used for APS classification. Epidemiology of obstetric APS varies from one population group to another largely due to different inclusion criteria and lack of standardization of antibody detection methods. Treatment is still controversial. This topic should include a multidisciplinary team and should be individualized. Success here is based on strict control and monitoring throughout pregnancy and even in the preconception and postpartum periods. Further research in this field and unification of criteria are required to yield better therapeutic strategies in the future. © 2011 Elsevier B.V. 2012 2020-05-26T00:00:08Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion 15689972 https://repository.urosario.edu.co/handle/10336/23166 https://doi.org/10.1016/j.autrev.2011.10.006 eng info:eu-repo/semantics/openAccess application/pdf instname:Universidad del Rosario
institution EdocUR - Universidad del Rosario
collection DSpace
language Inglés (English)
topic Acetylsalicylic acid
Antibody
Antithrombin
Autoantibody
Beta 2 glycoprotein 1 antibody
Betamethasone
Cardiolipin antibody
Dalteparin
Dexamethasone
Enoxaparin
Heparin
Low molecular weight heparin
Lupus anticoagulant
Nadroparin
Prednisolone
Prednisone
Unclassified drug
Warfarin
Antibody detection
Antiphospholipid syndrome
Autoimmune disease
Human
Hypercoagulability
Laboratory test
Low drug dose
Morbidity
Nonhuman
Preconception injury
Pregnancy
Puerperium
Review
Spontaneous abortion
Standardization
Teratogenicity
Thrombosis
Vascular disease
Animals
Antibody-dependent cell cytotoxicity
Antiphospholipid syndrome
Aspirin
Blood coagulation
Female
Heparin
Humans
Immunotherapy
Individualized medicine
Mice
Pregnancy
Pregnancy complications
Antiphospholipid antibodies
Obstetric antiphospholipid syndrome
Recurrent pregnancy miscarriage
animal
antiphospholipid
habitual
Abortion
Antibodies
Disease models
spellingShingle Acetylsalicylic acid
Antibody
Antithrombin
Autoantibody
Beta 2 glycoprotein 1 antibody
Betamethasone
Cardiolipin antibody
Dalteparin
Dexamethasone
Enoxaparin
Heparin
Low molecular weight heparin
Lupus anticoagulant
Nadroparin
Prednisolone
Prednisone
Unclassified drug
Warfarin
Antibody detection
Antiphospholipid syndrome
Autoimmune disease
Human
Hypercoagulability
Laboratory test
Low drug dose
Morbidity
Nonhuman
Preconception injury
Pregnancy
Puerperium
Review
Spontaneous abortion
Standardization
Teratogenicity
Thrombosis
Vascular disease
Animals
Antibody-dependent cell cytotoxicity
Antiphospholipid syndrome
Aspirin
Blood coagulation
Female
Heparin
Humans
Immunotherapy
Individualized medicine
Mice
Pregnancy
Pregnancy complications
Antiphospholipid antibodies
Obstetric antiphospholipid syndrome
Recurrent pregnancy miscarriage
animal
antiphospholipid
habitual
Abortion
Antibodies
Disease models
Galarza-Maldonado, Claudio
Kourilovitch, Maria R.
Pérez-Fernández, Oscar M.
Gaybor, Mariana
Cordero, Christian
Cabrera, Sonia
Soroka, Nikolai F.
Obstetric antiphospholipid syndrome
description Antiphospholipid syndrome (APS) in pregnancy has a serious impact on maternal and fetal morbidity. It causes recurrent pregnancy miscarriage and it is associated with other adverse obstetric findings like preterm delivery, intrauterine growth restriction, preeclampsia, HELLP syndrome and others. The 2006 revised criteria, which is still valid, is used for APS classification. Epidemiology of obstetric APS varies from one population group to another largely due to different inclusion criteria and lack of standardization of antibody detection methods. Treatment is still controversial. This topic should include a multidisciplinary team and should be individualized. Success here is based on strict control and monitoring throughout pregnancy and even in the preconception and postpartum periods. Further research in this field and unification of criteria are required to yield better therapeutic strategies in the future. © 2011 Elsevier B.V.
format Artículo (Article)
author Galarza-Maldonado, Claudio
Kourilovitch, Maria R.
Pérez-Fernández, Oscar M.
Gaybor, Mariana
Cordero, Christian
Cabrera, Sonia
Soroka, Nikolai F.
author_facet Galarza-Maldonado, Claudio
Kourilovitch, Maria R.
Pérez-Fernández, Oscar M.
Gaybor, Mariana
Cordero, Christian
Cabrera, Sonia
Soroka, Nikolai F.
author_sort Galarza-Maldonado, Claudio
title Obstetric antiphospholipid syndrome
title_short Obstetric antiphospholipid syndrome
title_full Obstetric antiphospholipid syndrome
title_fullStr Obstetric antiphospholipid syndrome
title_full_unstemmed Obstetric antiphospholipid syndrome
title_sort obstetric antiphospholipid syndrome
publishDate 2012
url https://repository.urosario.edu.co/handle/10336/23166
https://doi.org/10.1016/j.autrev.2011.10.006
_version_ 1740172774625771520
score 12,131701